Keith Wharton has 30+ years of experience in academic and biopharma settings, including Leica Biosystems, Novartis, and Biogen. Following board certification in anatomic pathology and fellowship training in autopsy pathology and developmental biology at Stanford University, he ran an NIH-funded research laboratory at UT Southwestern Medical Center and held several leadership positions including Pathology course director, Director of the Laboratory of Molecular Pathology, and Associate Dean.
Objectives of this webinar are monoplex vs Multiplex staining, Multiplexing in research including biopharma and drug development and Pathways to clinical implementation.
Objectives of this webinar are monoplex vs Multiplex staining, Multiplexing in research including biopharma and drug development and Pathways to clinical implementation.
Current technology allows tumors to be painted with multiple colors, termed multiplex staining. Multiplex staining today used in research, may also assist with cancer diagnoses clinically via: preservation of tissue, improved diagnostic accuracy, and enhanced diagnostic insight.
In this webinar, Dr. Keith Wharton reviews a set of published studies using single cell analysis of lung tissues that have provided groundbreaking insight into lung development and disease.
